Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Exploration of targeted anti-tumor therapy Ročník 3; číslo 2; s. 172 - 199
Hlavní autoři: Skolariki, Aglaia, D’Costa, Jamie, Little, Martin, Lord, Simon
Médium: Journal Article
Jazyk:angličtina
Vydáno: Open Exploration 2022
Open Exploration Publishing Inc
Témata:
breast cancer
endocrine therapy
pi3k/akt/mtor pathway
Review
ISSN:2692-3114, 2692-3114
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions.
AbstractList The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions.
The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions.The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions.
Author Little, Martin
Lord, Simon
D’Costa, Jamie
Skolariki, Aglaia
Author_xml – sequence: 1
  givenname: Aglaia
  orcidid: 0000-0001-5354-0359
  surname: Skolariki
  fullname: Skolariki, Aglaia
  organization: Department of Oncology, University of Oxford, Churchill Hospital, OX3 7LE Oxford, UK
– sequence: 2
  givenname: Jamie
  orcidid: 0000-0002-6644-0661
  surname: D’Costa
  fullname: D’Costa, Jamie
  organization: Department of Oncology, University of Oxford, Churchill Hospital, OX3 7LE Oxford, UK
– sequence: 3
  givenname: Martin
  orcidid: 0000-0003-2592-1570
  surname: Little
  fullname: Little, Martin
  organization: Department of Oncology, Churchill Hospital, OX3 7LE Oxford, UK
– sequence: 4
  givenname: Simon
  orcidid: 0000-0001-7946-5609
  surname: Lord
  fullname: Lord, Simon
  organization: Department of Oncology, University of Oxford, Churchill Hospital, OX3 7LE Oxford, UK
BookMark eNp1kc1vEzEQxVeoiJbSO0cfuSTx9wcHpKoqEFGpKCpny-sdpy4bO9gOqP89m6RIFInTWJ73fpqZ97o7STlB170leM4U42YBzbU5xZTOMcZKv-jOqDR0xgjhJ3-9T7uLWh8mCdVYG0JfdadMYi41Z2fdapVHQDmgr0v2ZXH5vS02d7crtHXt_pd7RDGhDQzRtZjWCNKQfYkJUIEaa3PJw3vk81S2DbWM_BhT9G-6l8GNFS6e6nn37eP13dXn2c3tp-XV5c3MM8H1TKs-GCoD67XiThjg1AiihqEHbAhoJjQH7rWigpCeYad6KYQO2jgiJFB23i2P3CG7B7stcePKo80u2sNHLmvrSot-BCsFldIMQQ8Bcx-wo4ED5koLqYZg5MT6cGRtd_20sIfUihufQZ93Ury36_zTGj6dXu2HefcEKPnHDmqzm1g9jKNLkHfVUoUNJhKbvVQepb7kWgsE6-OUZMx7chwtwfaQr93na_f52kO-kxH_Y_wz338tvwG7Iafp
CitedBy_id crossref_primary_10_1038_s41523_024_00645_3
crossref_primary_10_3390_cancers16030678
crossref_primary_10_3390_cancers16101862
crossref_primary_10_1016_j_bcp_2025_116850
crossref_primary_10_1016_j_biopha_2023_115676
crossref_primary_10_3390_ijms23169008
crossref_primary_10_1002_ijc_70067
crossref_primary_10_1016_j_canlet_2023_216058
crossref_primary_10_1177_10915818231200419
crossref_primary_10_1016_j_critrevonc_2025_104707
Cites_doi 10.1093/carcin/bgr303
10.1074/jbc.r100029200
10.1158/1078-0432.ccr-18-0613
10.1001/jamaoncol.2018.4475
10.1101/cshperspect.a026609
10.1200/jco.2021.39.15_suppl.tps1101
10.1056/nejmoa1009290
10.1128/mcb.18.3.1379
10.1593/tlo.09277
10.1186/s12943-019-0954-x
10.1200/jco.2021.39.15_suppl.1057
10.1038/ng.556
10.1158/1078-0432.ccr-20-2114
10.1038/nature07091
10.1158/2159-8290.cd-17-0151
10.1158/0008-5472.can-10-2274
10.1016/s0021-9258(17)41901-6
10.1158/1078-0432.ccr-15-0588
10.1158/1535-7163.mct-11-0824-t
10.1093/annonc/mdu497
10.1186/s13058-014-0406-x
10.1200/JCO.2017.73.0143
10.3410/f.732279400.793559076
10.1016/j.molcel.2008.05.025
10.1016/s0960-9822(00)00177-9
10.4161/cbt.3.8.994
10.1210/jc.2010-2644
10.1038/nrclinonc.2018.28
10.2217/fon.12.49
10.1007/s10549-015-3615-9
10.1056/nejmoa066838
10.1016/s0140-6736(16)32419-9
10.1016/0092-8674(91)90410-z
10.1038/modpathol.3800525
10.1007/s10549-014-3082-8
10.1016/j.semcdb.2014.08.006
10.1095/biolreprod58.3.627
10.1186/s13045-019-0754-1
10.1158/1535-7163.mct-13-0655
10.1002/j.1460-2075.1994.tb06577.x
10.1200/jco.2011.39.0708
10.1200/jco.2011.36.1360
10.1016/s1470-2045(13)70026-3
10.1038/s41467-019-09068-2
10.1158/0008-5472.can-08-2755
10.3390/cancers13143517
10.3390/ijms22157812
10.1038/s41698-017-0017-y
10.1158/1535-7163.mct-09-1012
10.1634/theoncologist.2018-0407
10.2217/bmt.12.37
10.1016/j.annonc.2020.10.596
10.1016/0092-8674(91)90411-q
10.1158/1078-0432.ccr-19-3953
10.3390/ijms22041743
10.1038/aps.2012.72
10.31525/ct1-nct04060862
10.1074/jbc.270.8.3662
10.1158/1078-0432.ccr-09-2828
10.18632/oncotarget.12742
10.1016/j.jsbmb.2005.11.013
10.1038/s41586-020-2502-7
10.1126/science.1096502
10.1200/jco.2014.32.15_suppl.2605
10.1200/po.19.00221
10.1001/jamaoncol.2018.2262
10.1128/mcb.14.6.3550-3558.1994
10.1158/1078-0432.ccr-16-0134
10.1038/nrm3290
10.1038/370527a0
10.3892/ijmm.2016.2833
10.1155/2014/565839
10.3390/cancers13071642
10.1038/srep06255
10.1158/1078-0432.ccr-09-1173
10.1038/modpathol.3800296
10.18632/oncoscience.307
10.1016/s0021-9258(18)98375-4
10.1016/0092-8674(92)90166-a
10.1200/jco.2016.34.15_suppl.530
10.1016/j.bone.2012.11.011
10.1016/s1470-2045(16)00106-6
10.1126/scitranslmed.3003293
10.1186/bcr2833
10.1200/jco.2018.36.15_suppl.1018
10.1001/jamaoncol.2019.2526
10.1016/s1470-2045(19)30817-4
10.1053/j.seminoncol.2020.05.010
10.3389/fcell.2021.641449
10.1186/s13058-020-01382-8
10.1007/s10911-013-9303-7
10.1073/pnas.87.4.1411
10.3390/cancers11121987
10.1242/jcs.093773
10.1007/s11357-020-00317-7
10.3410/f.727683217.793533460
10.3389/fonc.2019.00666
10.1093/annonc/mdx365.004
10.1007/s10549-017-4375-5
10.1073/pnas.95.23.13513
10.1200/jco.2017.76.9331
10.1371/journal.pone.0140479
10.1158/1538-7445.sabcs19-p1-19-46
10.1158/1078-0432.ccr-12-1141
10.3390/cancers13164013
10.1056/nejmoa1813904
10.1093/annonc/mdw562
10.7150/jca.40531
10.1172/JCI73939
10.1016/j.annonc.2020.11.011
10.1016/s1470-2045(21)00034-6
10.1186/bcr3599
10.1016/j.cell.2017.07.029
10.1016/j.bbadis.2011.05.001
10.1016/j.ccr.2014.05.020
10.1016/j.ccell.2018.08.008
10.1158/0008-5472.can-12-3385
10.1158/1538-7445.sabcs15-p4-13-27
10.1158/1538-7445.am2016-ct061
10.1016/0092-8674(91)90409-r
10.1073/pnas.88.18.7908
10.1038/cr.2015.133
10.1111/bcpt.12457
10.1200/jco.2018.36.15_suppl.1040
10.1016/s0959-8049(14)00221-4
10.1158/1078-0432.ccr-14-0868
10.1007/bf02967472
10.1042/0264-6021:3460561
10.2174/092986713804999303
10.1038/nature07782
10.1158/2159-8290.cd-16-0795
10.1200/JCO.2012.46.2655
10.1093/annonc/mdw320
10.1074/jbc.272.50.31515
10.1158/2159-8290.cd-20-0553
10.1186/1471-2407-13-545
10.1200/jco.2015.63.9179
10.1056/nejmoa1109653
10.1158/1538-7445.am2014-lb-327
10.1158/1078-0432.ccr-20-4131
10.1200/jco.2011.38.3331
10.1210/jcem.82.12.4470
10.1158/1078-0432.ccr-12-3072
10.1200/jco.2014.60.1971
10.2147/bctt.s60696
10.1073/pnas.91.16.7415
10.1038/nature17963
10.1016/s0021-9258(17)41801-1
10.1091/mbc.e08-12-1249
10.1001/jamaoncol.2018.0060
10.1159/000132325
10.1200/jco.2020.38.15_suppl.1066
10.1158/2159-8290.cd-16-0512
10.1158/1078-0432.ccr-13-0884
10.1038/nature11412
10.1038/nrm2672
10.1002/ijc.30457
10.1083/jcb.200403069
10.1016/j.celrep.2013.12.035
10.1158/1078-0432.ccr-18-3160
10.1158/1535-7163.mct-12-0993-t
10.1007/s10549-009-0575-y
10.1016/s1470-2045(19)30334-1
10.1186/s40842-021-00125-8
10.3390/ijms21239175
10.1158/0008-5472.can-11-1295
10.1126/science.1106148
10.1016/j.ejca.2021.03.042
10.1016/s0140-6736(08)61039-9
10.1056/nejmoa1001671
10.1158/1535-7163.mct-11-0474
10.1007/s10549-013-2528-8
10.1371/journal.pone.0166125
10.1158/1078-0432.ccr-08-1763
10.1158/1078-0432.ccr-21-1095
10.1158/1535-7163.mct-13-0842
10.1001/jamaoncol.2016.1279
10.1186/s13058-020-01320-8
10.1634/theoncologist.2015-0248
10.1038/332644a0
10.1158/1078-0432.ccr-15-2160
10.1038/s41586-018-0343-4
10.1074/jbc.m010840200
10.1016/j.annonc.2020.08.452
10.1007/s12325-013-0060-1
10.1158/1538-7445.sabcs15-p5-13-04
10.1158/1078-0432.ccr-20-1008
ContentType Journal Article
Copyright The Author(s) 2022.
The Author(s) 2022. 2022
Copyright_xml – notice: The Author(s) 2022.
– notice: The Author(s) 2022. 2022
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.37349/etat.2022.00078
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 2692-3114
EndPage 199
ExternalDocumentID oai_doaj_org_article_652669df8df04cf0a2f4e0478567df96
PMC9400772
10_37349_etat_2022_00078
GrantInformation_xml – fundername: ;
  grantid: ACF-2020-13-009
– fundername: ;
  grantid: 1415
GroupedDBID AAYXX
ALMA_UNASSIGNED_HOLDINGS
CITATION
GROUPED_DOAJ
M~E
OK1
PGMZT
RPM
7X8
5PM
ID FETCH-LOGICAL-c3548-87bf926f3b874a59e429517ddbe091e83584e4c872511b30a7b6558f89a156e23
IEDL.DBID DOA
ISSN 2692-3114
IngestDate Fri Oct 03 12:50:56 EDT 2025
Thu Aug 21 18:29:10 EDT 2025
Sun Nov 09 09:38:53 EST 2025
Sat Nov 29 03:59:15 EST 2025
Tue Nov 18 22:25:55 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3548-87bf926f3b874a59e429517ddbe091e83584e4c872511b30a7b6558f89a156e23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-6644-0661
0000-0001-7946-5609
0000-0003-2592-1570
0000-0001-5354-0359
OpenAccessLink https://doaj.org/article/652669df8df04cf0a2f4e0478567df96
PMID 36046843
PQID 2709016092
PQPubID 23479
PageCount 28
ParticipantIDs doaj_primary_oai_doaj_org_article_652669df8df04cf0a2f4e0478567df96
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9400772
proquest_miscellaneous_2709016092
crossref_citationtrail_10_37349_etat_2022_00078
crossref_primary_10_37349_etat_2022_00078
PublicationCentury 2000
PublicationDate 2022-00-00
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – year: 2022
  text: 2022-00-00
PublicationDecade 2020
PublicationTitle Exploration of targeted anti-tumor therapy
PublicationYear 2022
Publisher Open Exploration
Open Exploration Publishing Inc
Publisher_xml – name: Open Exploration
– name: Open Exploration Publishing Inc
References ref57
ref56
ref59
ref58
ref53
ref52
ref55
ref54
ref51
ref50
ref46
ref45
ref48
ref47
ref42
ref41
ref44
ref43
ref49
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref100
ref101
ref40
ref35
ref34
ref37
ref36
ref31
ref30
ref33
ref32
ref39
ref38
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref128
ref129
ref97
ref126
ref96
ref127
ref99
ref124
ref98
ref125
ref93
ref133
ref92
ref134
ref95
ref131
ref94
ref132
ref130
ref91
ref90
ref89
ref139
ref86
ref137
ref85
ref138
ref88
ref135
ref87
ref136
ref82
ref144
ref81
ref145
ref84
ref142
ref83
ref143
ref140
ref141
ref80
ref79
ref108
ref78
ref109
ref106
ref107
ref75
ref104
ref74
ref105
ref77
ref102
ref76
ref103
ref71
ref111
ref70
ref112
ref73
ref72
ref110
ref68
ref119
ref67
ref117
ref69
ref118
ref64
ref115
ref63
ref116
ref66
ref113
ref65
ref114
ref60
ref122
ref123
ref62
ref120
ref61
ref121
ref168
ref169
ref170
ref177
ref178
ref175
ref176
ref173
ref174
ref171
ref172
ref179
ref180
ref181
ref188
ref189
ref186
ref187
ref184
ref185
ref182
ref183
ref148
ref149
ref146
ref147
ref155
ref156
ref153
ref154
ref151
ref152
ref150
ref159
ref157
ref158
ref166
ref167
ref164
ref165
ref162
ref163
ref160
ref161
ref13
ref12
ref15
ref14
ref11
ref10
ref17
ref16
ref19
ref18
ref0
ref2
ref1
ref191
ref192
ref190
References_xml – ident: ref57
  doi: 10.1093/carcin/bgr303
– ident: ref45
  doi: 10.1074/jbc.r100029200
– ident: ref108
  doi: 10.1158/1078-0432.ccr-18-0613
– ident: ref99
  doi: 10.1001/jamaoncol.2018.4475
– ident: ref31
  doi: 10.1101/cshperspect.a026609
– ident: ref180
  doi: 10.1200/jco.2021.39.15_suppl.tps1101
– ident: ref123
  doi: 10.1056/nejmoa1009290
– ident: ref22
  doi: 10.1128/mcb.18.3.1379
– ident: ref73
  doi: 10.1593/tlo.09277
– ident: ref61
  doi: 10.1186/s12943-019-0954-x
– ident: ref136
  doi: 10.1200/jco.2021.39.15_suppl.1057
– ident: ref60
  doi: 10.1038/ng.556
– ident: ref92
  doi: 10.1158/1078-0432.ccr-20-2114
– ident: ref161
  doi: 10.1038/nature07091
– ident: ref145
  doi: 10.1158/2159-8290.cd-17-0151
– ident: ref79
  doi: 10.1158/0008-5472.can-10-2274
– ident: ref11
  doi: 10.1016/s0021-9258(17)41901-6
– ident: ref139
  doi: 10.1158/1078-0432.ccr-15-0588
– ident: ref71
  doi: 10.1158/1535-7163.mct-11-0824-t
– ident: ref127
  doi: 10.1093/annonc/mdu497
– ident: ref185
  doi: 10.1186/s13058-014-0406-x
– ident: ref69
  doi: 10.1200/JCO.2017.73.0143
– ident: ref95
  doi: 10.3410/f.732279400.793559076
– ident: ref74
– ident: ref26
  doi: 10.1016/j.molcel.2008.05.025
– ident: ref9
  doi: 10.1016/s0960-9822(00)00177-9
– ident: ref50
  doi: 10.4161/cbt.3.8.994
– ident: ref66
  doi: 10.1210/jc.2010-2644
– ident: ref83
  doi: 10.1038/nrclinonc.2018.28
– ident: ref141
  doi: 10.2217/fon.12.49
– ident: ref101
  doi: 10.1007/s10549-015-3615-9
– ident: ref120
  doi: 10.1056/nejmoa066838
– ident: ref0
  doi: 10.1016/s0140-6736(16)32419-9
– ident: ref20
  doi: 10.1016/0092-8674(91)90410-z
– ident: ref56
  doi: 10.1038/modpathol.3800525
– ident: ref75
  doi: 10.1007/s10549-014-3082-8
– ident: ref34
  doi: 10.1016/j.semcdb.2014.08.006
– ident: ref44
  doi: 10.1095/biolreprod58.3.627
– ident: ref32
  doi: 10.1186/s13045-019-0754-1
– ident: ref187
  doi: 10.1158/1535-7163.mct-13-0655
– ident: ref17
  doi: 10.1002/j.1460-2075.1994.tb06577.x
– ident: ref88
  doi: 10.1200/jco.2011.39.0708
– ident: ref166
  doi: 10.1200/jco.2011.36.1360
– ident: ref137
  doi: 10.1016/s1470-2045(13)70026-3
– ident: ref191
  doi: 10.1038/s41467-019-09068-2
– ident: ref80
  doi: 10.1158/0008-5472.can-08-2755
– ident: ref115
  doi: 10.3390/cancers13143517
– ident: ref179
  doi: 10.3390/ijms22157812
– ident: ref76
  doi: 10.1038/s41698-017-0017-y
– ident: ref151
  doi: 10.1158/1535-7163.mct-09-1012
– ident: ref142
  doi: 10.1634/theoncologist.2018-0407
– ident: ref46
  doi: 10.2217/bmt.12.37
– ident: ref107
  doi: 10.1016/j.annonc.2020.10.596
– ident: ref19
  doi: 10.1016/0092-8674(91)90411-q
– ident: ref157
  doi: 10.1158/1078-0432.ccr-19-3953
– ident: ref116
  doi: 10.3390/ijms22041743
– ident: ref82
  doi: 10.1038/aps.2012.72
– ident: ref158
  doi: 10.31525/ct1-nct04060862
– ident: ref23
  doi: 10.1074/jbc.270.8.3662
– ident: ref64
  doi: 10.1158/1078-0432.ccr-09-2828
– ident: ref119
  doi: 10.18632/oncotarget.12742
– ident: ref15
  doi: 10.1016/j.jsbmb.2005.11.013
– ident: ref177
  doi: 10.1038/s41586-020-2502-7
– ident: ref13
  doi: 10.1126/science.1096502
– ident: ref97
  doi: 10.1200/jco.2014.32.15_suppl.2605
– ident: ref192
  doi: 10.1200/po.19.00221
– ident: ref86
  doi: 10.1001/jamaoncol.2018.2262
– ident: ref16
  doi: 10.1128/mcb.14.6.3550-3558.1994
– ident: ref98
  doi: 10.1158/1078-0432.ccr-16-0134
– ident: ref2
  doi: 10.1038/nrm3290
– ident: ref8
  doi: 10.1038/370527a0
– ident: ref18
  doi: 10.3892/ijmm.2016.2833
– ident: ref25
  doi: 10.1155/2014/565839
– ident: ref183
  doi: 10.3390/cancers13071642
– ident: ref53
  doi: 10.1038/srep06255
– ident: ref55
  doi: 10.1158/1078-0432.ccr-09-1173
– ident: ref59
  doi: 10.1038/modpathol.3800296
– ident: ref190
  doi: 10.18632/oncoscience.307
– ident: ref24
  doi: 10.1016/s0021-9258(18)98375-4
– ident: ref6
  doi: 10.1016/0092-8674(92)90166-a
– ident: ref135
  doi: 10.1200/jco.2016.34.15_suppl.530
– ident: ref43
  doi: 10.1016/j.bone.2012.11.011
– ident: ref100
  doi: 10.1016/s1470-2045(16)00106-6
– ident: ref173
  doi: 10.1126/scitranslmed.3003293
– ident: ref65
  doi: 10.1186/bcr2833
– ident: ref131
  doi: 10.1200/jco.2018.36.15_suppl.1018
– ident: ref91
  doi: 10.1001/jamaoncol.2019.2526
– ident: ref112
  doi: 10.1016/s1470-2045(19)30817-4
– ident: ref1
  doi: 10.1053/j.seminoncol.2020.05.010
– ident: ref134
  doi: 10.3389/fcell.2021.641449
– ident: ref93
  doi: 10.1186/s13058-020-01382-8
– ident: ref174
  doi: 10.1007/s10911-013-9303-7
– ident: ref5
  doi: 10.1073/pnas.87.4.1411
– ident: ref68
  doi: 10.3390/cancers11121987
– ident: ref14
  doi: 10.1242/jcs.093773
– ident: ref175
  doi: 10.1007/s11357-020-00317-7
– ident: ref94
  doi: 10.3410/f.727683217.793533460
– ident: ref181
  doi: 10.3389/fonc.2019.00666
– ident: ref156
  doi: 10.1093/annonc/mdx365.004
– ident: ref140
  doi: 10.1007/s10549-017-4375-5
– ident: ref27
  doi: 10.1073/pnas.95.23.13513
– ident: ref89
  doi: 10.1200/jco.2017.76.9331
– ident: ref152
  doi: 10.1371/journal.pone.0140479
– ident: ref111
  doi: 10.1158/1538-7445.sabcs19-p1-19-46
– ident: ref67
  doi: 10.1158/1078-0432.ccr-12-1141
– ident: ref176
  doi: 10.3390/cancers13164013
– ident: ref84
  doi: 10.1056/nejmoa1813904
– ident: ref148
  doi: 10.1093/annonc/mdw562
– ident: ref189
  doi: 10.7150/jca.40531
– ident: ref35
  doi: 10.1172/JCI73939
– ident: ref96
  doi: 10.1016/j.annonc.2020.11.011
– ident: ref102
  doi: 10.1016/s1470-2045(21)00034-6
– ident: ref186
  doi: 10.1186/bcr3599
– ident: ref3
  doi: 10.1016/j.cell.2017.07.029
– ident: ref42
  doi: 10.1016/j.bbadis.2011.05.001
– ident: ref162
  doi: 10.1016/j.ccr.2014.05.020
– ident: ref51
  doi: 10.1016/j.ccell.2018.08.008
– ident: ref77
  doi: 10.1158/0008-5472.can-12-3385
– ident: ref130
  doi: 10.1158/1538-7445.sabcs15-p4-13-27
– ident: ref12
– ident: ref129
  doi: 10.1158/1538-7445.am2016-ct061
– ident: ref21
  doi: 10.1016/0092-8674(91)90409-r
– ident: ref58
– ident: ref7
  doi: 10.1073/pnas.88.18.7908
– ident: ref117
  doi: 10.1038/cr.2015.133
– ident: ref133
– ident: ref171
  doi: 10.1111/bcpt.12457
– ident: ref114
  doi: 10.1200/jco.2018.36.15_suppl.1040
– ident: ref125
  doi: 10.1016/s0959-8049(14)00221-4
– ident: ref154
  doi: 10.1158/1078-0432.ccr-14-0868
– ident: ref47
  doi: 10.1007/bf02967472
– ident: ref29
  doi: 10.1042/0264-6021:3460561
– ident: ref39
  doi: 10.2174/092986713804999303
– ident: ref178
  doi: 10.1038/nature07782
– ident: ref165
  doi: 10.1158/2159-8290.cd-16-0795
– ident: ref128
  doi: 10.1200/JCO.2012.46.2655
– ident: ref147
  doi: 10.1093/annonc/mdw320
– ident: ref28
  doi: 10.1074/jbc.272.50.31515
– ident: ref110
  doi: 10.1158/2159-8290.cd-20-0553
– ident: ref150
  doi: 10.1186/1471-2407-13-545
– ident: ref149
  doi: 10.1200/jco.2015.63.9179
– ident: ref85
  doi: 10.1056/nejmoa1109653
– ident: ref160
  doi: 10.1158/1538-7445.am2014-lb-327
– ident: ref90
  doi: 10.1158/1078-0432.ccr-20-4131
– ident: ref87
  doi: 10.1200/jco.2011.38.3331
– ident: ref40
  doi: 10.1210/jcem.82.12.4470
– ident: ref72
  doi: 10.1158/1078-0432.ccr-12-3072
– ident: ref143
  doi: 10.1200/jco.2014.60.1971
– ident: ref52
  doi: 10.2147/bctt.s60696
– ident: ref37
– ident: ref10
  doi: 10.1073/pnas.91.16.7415
– ident: ref118
  doi: 10.1038/nature17963
– ident: ref38
  doi: 10.1016/s0021-9258(17)41801-1
– ident: ref36
  doi: 10.1091/mbc.e08-12-1249
– ident: ref126
  doi: 10.1001/jamaoncol.2018.0060
– ident: ref41
  doi: 10.1159/000132325
– ident: ref113
  doi: 10.1200/jco.2020.38.15_suppl.1066
– ident: ref164
  doi: 10.1158/2159-8290.cd-16-0512
– ident: ref146
  doi: 10.1158/1078-0432.ccr-13-0884
– ident: ref49
  doi: 10.1038/nature11412
– ident: ref33
  doi: 10.1038/nrm2672
– ident: ref153
  doi: 10.1002/ijc.30457
– ident: ref159
  doi: 10.1083/jcb.200403069
– ident: ref163
  doi: 10.1016/j.celrep.2013.12.035
– ident: ref105
  doi: 10.1158/1078-0432.ccr-18-3160
– ident: ref63
  doi: 10.1158/1535-7163.mct-12-0993-t
– ident: ref54
  doi: 10.1007/s10549-009-0575-y
– ident: ref109
  doi: 10.1016/s1470-2045(19)30334-1
– ident: ref169
  doi: 10.1186/s40842-021-00125-8
– ident: ref172
  doi: 10.3390/ijms21239175
– ident: ref81
  doi: 10.1158/0008-5472.can-11-1295
– ident: ref30
  doi: 10.1126/science.1106148
– ident: ref103
  doi: 10.1016/j.ejca.2021.03.042
– ident: ref121
  doi: 10.1016/s0140-6736(08)61039-9
– ident: ref122
  doi: 10.1056/nejmoa1001671
– ident: ref62
  doi: 10.1158/1535-7163.mct-11-0474
– ident: ref138
  doi: 10.1007/s10549-013-2528-8
– ident: ref170
  doi: 10.1371/journal.pone.0166125
– ident: ref184
  doi: 10.1158/1078-0432.ccr-08-1763
– ident: ref106
  doi: 10.1158/1078-0432.ccr-21-1095
– ident: ref78
  doi: 10.1158/1535-7163.mct-13-0842
– ident: ref144
  doi: 10.1001/jamaoncol.2016.1279
– ident: ref182
  doi: 10.1186/s13058-020-01320-8
– ident: ref168
  doi: 10.1634/theoncologist.2015-0248
– ident: ref4
  doi: 10.1038/332644a0
– ident: ref155
  doi: 10.1158/1078-0432.ccr-15-2160
– ident: ref167
  doi: 10.1038/s41586-018-0343-4
– ident: ref48
  doi: 10.1074/jbc.m010840200
– ident: ref132
  doi: 10.1016/j.annonc.2020.08.452
– ident: ref124
  doi: 10.1007/s12325-013-0060-1
– ident: ref70
  doi: 10.1158/1538-7445.sabcs15-p5-13-04
– ident: ref104
  doi: 10.1158/1078-0432.ccr-20-1008
– ident: ref188
SSID ssj0002808912
Score 2.2532146
SecondaryResourceType review_article
Snippet The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment....
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 172
SubjectTerms breast cancer
endocrine therapy
pi3k/akt/mtor pathway
Review
Title Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
URI https://www.proquest.com/docview/2709016092
https://pubmed.ncbi.nlm.nih.gov/PMC9400772
https://doaj.org/article/652669df8df04cf0a2f4e0478567df96
Volume 3
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2692-3114
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002808912
  issn: 2692-3114
  databaseCode: DOA
  dateStart: 20200101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2692-3114
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002808912
  issn: 2692-3114
  databaseCode: M~E
  dateStart: 20200101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWg4sAFtQLEAq2MxIVDlNR2Mja3gloVIUq1KtLeLH-MxUJJULst6oXfztjZVpsLXLjkkDiK_TzxzNgzbxh7rWTUoBVWgoyLijS-r4yDtopKoYIu0sroS7EJODnRi4U53Sj1lWPCRnrgEbi6a0mFmJh0TI0KqXEiKcyUMm0HMZlCtk1Wz4Yz9a1sGTXa7IvxXFKCVKbO0XvkD4pC0Jmrqm3ooULXP7ExpxGSGyrnaJs9WtuK_GDs4w67h_1jNp8P58iHxE8_yI_1wfdV_ePs85znysK_3A1f9rwkg-RoZo59HEJO7-PkVGdDkWb4LQ9jpiJfDXzMi3zCvhwdnr0_rtaFEaogycOgFcwnI7okvQblWoOkVNp9iNEjqX8ko4rQV0FD9h-8bBz4rm110saRu4ZCPmVb_dDjM8ZpnfQtYNACjUKnfGjQgZMoPEDq1IzVtzDZsGYNz8Urzi15DwVYm4G1GVhbgJ2xN3dv_BwZM_7S9l1G_q5d5rouN0gC7FoC7L8kYMZe3c6bpX8jH3i4HoerSyugMZlBz4gZg8mETr44fdIvvxaW7VIxHsTz_9HFF-xhHvS4dfOSba0urnCXPQjXq-XlxR67Dwu9VwSYrp9-H_4B6Kn1Bw
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+PI3K%2FAkt%2FmTOR+pathway+in+mediating+endocrine+resistance%3A+concept+to+clinic&rft.jtitle=Exploration+of+targeted+anti-tumor+therapy&rft.au=Skolariki%2C+Aglaia&rft.au=D%E2%80%99Costa%2C+Jamie&rft.au=Little%2C+Martin&rft.au=Lord%2C+Simon&rft.date=2022&rft.pub=Open+Exploration&rft.eissn=2692-3114&rft.volume=3&rft.issue=2&rft.spage=172&rft.epage=199&rft_id=info:doi/10.37349%2Fetat.2022.00078&rft_id=info%3Apmid%2F36046843&rft.externalDocID=PMC9400772
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2692-3114&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2692-3114&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2692-3114&client=summon